Free Lung NGS Biomarker Testing Launched for Cancer Patients
In a significant move to drive awareness about precision oncology, free Lung NGS (Next Generation Sequencing) biomarker testing has been launched for lung cancer patients across India. This cutting-edge test identifies mutations corresponding to approved therapies by the FDA (Food and Drug Administration) and the National Comprehensive Cancer Network (NCCN). This initiative is backed by leading pharmaceutical companies as part of their Corporate Social Responsibility (CSR) efforts.
Lung cancer is one of the most common types of cancer, with a high mortality rate globally. According to the World Health Organization (WHO), lung cancer accounts for 11.6% of all cancer cases and 18.4% of all cancer-related deaths. India is no exception, with lung cancer being the second most common cancer in the country. The disease is often diagnosed at a late stage, making treatment challenging and survival rates poor.
The launch of free Lung NGS biomarker testing is a significant step towards improving the diagnosis and treatment of lung cancer. NGS is a powerful tool that enables the simultaneous analysis of multiple genes in a single test. This test can identify genetic mutations that are associated with specific types of lung cancer, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The test is designed to identify mutations corresponding to approved therapies by the FDA and NCCN. These therapies include targeted therapies, such as EGFR and ALK inhibitors, and immunotherapies, such as PD-1 and PD-L1 inhibitors. By identifying these mutations, healthcare providers can recommend targeted therapies that are more effective and have fewer side effects.
The launch of free Lung NGS biomarker testing is a significant initiative that has the potential to improve the lives of lung cancer patients. The test is available to patients across India, and is being offered free of cost by leading pharmaceutical companies as part of their CSR efforts.
Precision oncology is a rapidly evolving field that is revolutionizing the way cancer is diagnosed and treated. The use of NGS and other advanced technologies is enabling healthcare providers to develop personalized treatment plans that are tailored to the unique needs of each patient.
The benefits of precision oncology are numerous. By identifying genetic mutations that are associated with specific types of cancer, healthcare providers can recommend targeted therapies that are more effective and have fewer side effects. This approach can improve patient outcomes, reduce the risk of side effects, and enhance the overall quality of life for patients.
The launch of free Lung NGS biomarker testing is a significant step towards improving the diagnosis and treatment of lung cancer. This initiative is a testament to the commitment of pharmaceutical companies to improving patient outcomes and driving awareness about precision oncology.
In conclusion, the launch of free Lung NGS biomarker testing is a significant initiative that has the potential to improve the lives of lung cancer patients across India. This cutting-edge test identifies mutations corresponding to approved therapies by the FDA and NCCN, and is available free of cost to patients across the country. This initiative is a testament to the commitment of pharmaceutical companies to improving patient outcomes and driving awareness about precision oncology.
Source:
https://thecsrjournal.in/csr-news-free-lung-ngs-biomarker-testing-lung-cancer-patients-india/
